$TEM — NEWS + TRADE SETUP 👀
📉 #short 🔴
Entry: $70.20–70.60 after rejection
TP1: $69.85
TP2: $69.50
SL: $71.55
Trigger: rejection below $70.70 + loss of $70.20.
If $71.47 breaks and holds, I don't want the short. That's the invalidation.
News is bullish.
Structure is currently giving me a short-term rejection setup.
Confirmation > prediction.
Tempus AI just got another FDA tailwind.
On Aug. 24, Tempus received FDA 510(k) clearance for ECG-PH, its AI software designed to detect signs associated with pulmonary hypertension. Another addition to its FDA-cleared AI portfolio.
But the market isn't giving it a free pass.
$TEM pushed to $71.47 and is now around $70.43, showing rejection from the local high. Recent selling from Tempus' CEO and ARK Invest also adds some pressure.
Not financial advice
$TEM
📉 #short 🔴
Entry: $70.20–70.60 after rejection
TP1: $69.85
TP2: $69.50
SL: $71.55
Trigger: rejection below $70.70 + loss of $70.20.
If $71.47 breaks and holds, I don't want the short. That's the invalidation.
News is bullish.
Structure is currently giving me a short-term rejection setup.
Confirmation > prediction.
Tempus AI just got another FDA tailwind.
On Aug. 24, Tempus received FDA 510(k) clearance for ECG-PH, its AI software designed to detect signs associated with pulmonary hypertension. Another addition to its FDA-cleared AI portfolio.
But the market isn't giving it a free pass.
$TEM pushed to $71.47 and is now around $70.43, showing rejection from the local high. Recent selling from Tempus' CEO and ARK Invest also adds some pressure.
Not financial advice
$TEM
